Skip to main content
Premium Trial:

Request an Annual Quote

J&J Teams with Foundation Medicine on Cancer Marker Studies

NEW YORK (GenomeWeb News) – Foundation Medicine today said that it will partner with Johnson & Johnson Pharmaceutical Research and Development in a biomarker identification collaboration.

Under the agreement, the partners will use Foundation Medicine's clinical cancer genomic test to identify biomarkers that will support J&JPRD's clinical development programs.

The Cambridge, Mass.-based company's cancer diagnostic test uses next-generation sequencing to analyze specimens for variations in over 200 cancer-related genes, and it is optimized for analysis of tissue complexities that are inherent in tumor genomes.

"Our test may help identify patients that are more likely to respond to targeted therapies, which could accelerate clinical development and give physicians additional ways to effectively treat patients," Foundation Medicine President and CEO Michael Pellini explained in a statement.

Financial terms of the agreement were not released.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.